Clinical Trial: Efficacy and Safety of Sirolimus with or Without Cyclosporin a in Chinese Patients with Aplastic Anemia Refractory/Intolerant to Cyclosporin a

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06802055) titled 'Efficacy and Safety of Sirolimus with or Without Cyclosporin a in Chinese Patients with Aplastic Anemia Refractory/Intolerant to Cyclosporin a' on Jan. 25.

Brief Summary: This is a single center, randomized, open-label, phase II study to compare the efficacy of sirolimus combined with cyclosporin A (CsA) to sirolimus alone in Chinese subjects with aplastic anemia refractory/intolerant to CsA. The safety would also be evaluated. Patients would be randomized to receive sirolimus alone or sirolimus combined with CsA. Treatment with sirolimus will be started at 1-3 mg once daily orally, with a target trough blood concentration of 4-12 n...